just noticed the RBS Morgans analyst report posted on Acrux's website:
Acrux
Bull's-eye
ACR has secured Eli Lilly as a commercialisation partner for Axiron, currently
pending FDA approval to treat testosterone deficiency in men. The deal was
above our expectations and a great outcome for the company. Buy retained.
High Volatility
Target price
A$3.19 (from A$2.29)
Price
A$2.43
Short term (0-60 days)
We consider this to be an excellent deal, delivered in line with pre-defined company timelines and
one which follows a robust negotiating process. Eli Lilly has significant experience in the mens
health arena and, in our view, will be a solid partner for ACR. Eli Lillys performance with respect
to Cialis (an erectile dysfunction treatment) is testament to this. We also view the quantum of the
deal positively, noting that it is ahead of recent deals in the space.
We would also make the comment that todays announcement marks, in our view, the start of a
new period of maturity for the company. With regulatory approval on the horizon for Axiron and a
substantial partner in place, we forecast on-going profitability for the company, assuming of
course that the product is launched on time and without incident, an achievable task, in our view.
Regarding royalties: "We forecast a tiered rate ranging from 12% and increasing to 20% by FY15"
Regarding dividend: "Accordingly, we
forecast an initial payout ratio of 10% in FY11, increasing to a payout ratio of 25% thereafter.
We note that with the significant US$87m payment due from Eli Lilly upon market approval of
Axiron suggests that a special dividend or other forms of capital management is likely in
2HFY11, although at this stage, we do not forecast any specifics."
Regarding probability of FDA approval for Axiron: "We have increased our probability of success for Axiron to 90%
(from 80%). Each 5pp change to our probability of success for this programme alters our
valuation by 15cps."
- Forums
- ASX - By Stock
- ACR
- share target price
share target price, page-10
-
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.8¢ |
Change
0.003(5.45%) |
Mkt cap ! $16.86M |
Open | High | Low | Value | Volume |
5.5¢ | 5.8¢ | 5.4¢ | $73.70K | 1.303M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 76865 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.8¢ | 101900 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.057 |
2 | 76865 | 0.056 |
1 | 35350 | 0.055 |
1 | 16012 | 0.054 |
2 | 113139 | 0.053 |
Price($) | Vol. | No. |
---|---|---|
0.058 | 101900 | 2 |
0.059 | 225945 | 1 |
0.060 | 115000 | 1 |
0.061 | 100000 | 1 |
0.062 | 116100 | 2 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
NEWS
Exceptional lithium assays uncovered at Falcon Lake – expanding mineralisation, big potential ahead
NEWS
Biotech innovator secures $5.5M R&D tax incentive refund – major boost for cutting-edge programs
ACR (ASX) Chart |